Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | FBP1 | P09467 | 3/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9179184 | 0.86 | MME (0.42) | TSHRALDH1A1AKR1C3CYP3A4CYP2C9 | |
| SCHEMBL28472907 | 0.86 | TRPA1 (0.52) | TSHRALDH1A1AKR1C3CYP3A4CYP2C9 | |
| SCHEMBL28957732 | 0.84 | CYP3A4 (0.53) | TSHRALDH1A1AKR1C3CYP3A4CYP2C9 | |
| SCHEMBL22303965 | 0.83 | RECQL (0.55) | TSHRALDH1A1AKR1C3CYP3A4CYP2C9 | |
| SCHEMBL2850504 | 0.83 | ALDH1A1 (0.39) | TSHRALDH1A1AKR1C3CYP3A4CYP2C9 | |
| SCHEMBL2850505 | 0.83 | ALDH1A1 (0.39) | TSHRALDH1A1AKR1C3CYP3A4CYP2C9 | |
| SCHEMBL12291966 | 0.80 | LMNA (0.51) | TSHRALDH1A1AKR1C3ESR1MEN1 | |
| SCHEMBL17629458 | 0.78 | LMNA (0.58) | MEN1KMT2A | |
| SCHEMBL872839 | 0.78 | LMNA (0.58) | MEN1KMT2A | |
| SCHEMBL18172863 | 0.78 | NR1I2 (0.40) | TSHRALDH1A1AKR1C3RECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 800 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633494-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-04-25 | — | — | US | claimed |
| US-11633495-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-04-25 | — | — | US | claimed |
| EP-4056594-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | Birdie Biopharmaceuticals Inc. (KY) | 2022-09-14 | — | — | EP | claimed |
| US-20200353093-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2020-11-12 | — | — | US | claimed |
| US-20200345860-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2020-11-05 | — | — | US | claimed |
| US-10780180-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-09-22 | — | — | US | claimed |
| US-10744206-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-08-18 | — | — | US | claimed |
| US-20190269790-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2019-09-05 | — | — | US | claimed |
| US-20190269789-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2019-09-05 | — | — | US | claimed |
| US-10328158-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2019-06-25 | — | — | US | claimed |
| EP-0954966-B1 | Polymeric controlled release compositions | ROHM & HAAS (US) | 2003-06-25 | — | — | EP | claimed |
| EP-0683435-B1 | Positive-working radiation-sensitive composition | AGFA GEVAERT AG (DE) | 1997-06-04 | — | — | EP | claimed |
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260144888-A1 | USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE | PIERRE FABRE MEDICAMENT (FR) | 2026-05-28 | — | — | US | disclosed |
| US-20260137822-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | ABDERA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4727586-A1 | ANTI-CD5 ANTIBODIES AND THEIR USES | Synthis Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2003043583-A2 | TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES | SEATTLE GENETICS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| EP-0961619-A4 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL MYERS SQUIBB CO (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-0961619-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998013059-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269790-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | TSHR 4707/4885ALDH1A1 1617/4885AKR1C3 2914/4885 |
| US-10744206-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | TSHR 4707/4885ALDH1A1 1617/4885AKR1C3 2914/4885 |
| US-11633494-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | TSHR 4707/4885ALDH1A1 1617/4885AKR1C3 2914/4885 |
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | H1-10, IGSF11, CD99 | TSHR 260/4885ALDH1A1 2977/4885AKR1C3 1455/4885 |
| US-20200345860-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | TSHR 4707/4885ALDH1A1 1617/4885AKR1C3 2914/4885 |
| US-11633495-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | TSHR 4707/4885ALDH1A1 1617/4885AKR1C3 2914/4885 |
| US-20190269789-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | TSHR 4707/4885ALDH1A1 1617/4885AKR1C3 2914/4885 |
| US-20260144888-A1 | USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE | IGF1R, CD44, MUC1 | TSHR 60/4885ALDH1A1 3043/4885AKR1C3 4048/4885 |
| US-10328158-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | TSHR 4707/4885ALDH1A1 1617/4885AKR1C3 2914/4885 |
| US-20260137822-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | FCGR2A, FCGR3B, FCGR1A | TSHR 61/4885ALDH1A1 3825/4885AKR1C3 3173/4885 |
| US-10780180-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | TSHR 4707/4885ALDH1A1 1617/4885AKR1C3 2914/4885 |
| US-20200353093-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | TSHR 4707/4885ALDH1A1 1617/4885AKR1C3 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.